|
Neoplasm Metastasis
|
0.380 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, our findings suggest that increased FGF-2 expression and increased FGFR-1 expression are associated with high-grade OEDs, and are correlated with the presence of metastasis and adverse outcomes in OTSCC patients.
|
30129658 |
2019 |
|
Neoplasm Metastasis
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
These mRNAs encode proteins that play significant roles in all aspects of malignancy including angiogenesis factors (VEGF, FGF-2), onco-proteins (c-myc, cyclin D1, ODC), pro-survival proteins (survivin, BCL-2) and proteins involved in tumor invasion and metastasis (MMP-9, heparanase).
|
18719377 |
2008 |
|
Neoplasm Metastasis
|
0.380 |
AlteredExpression
|
phenotype |
BEFREE |
We also demonstrate that: (1) among the major pro-angiogenic genes, FGF-2 was not increased before or after irradiation and vascular endothelial growth factor strongly inhibited after irradiation; (2) expression of two important metalloproteinases, matrix metalloproteinase 2 and 9, involved in melanoma metastasis were decreased before and after irradiation; (3) expression of their major inhibitor, tissue inhibitor of metalloproteinase, was mainly upregulated; and (4) that invasion of BRCA1 downregulated cells was modified.
|
15009718 |
2004 |
|
Neoplasm Metastasis
|
0.380 |
AlteredExpression
|
phenotype |
BEFREE |
Increased FGF-2 mRNA expression was independently associated with the findings of lymph node invasion (R(2) = 0.71; P < 0.001) and distant metastasis (R(2) = 0.55; P = 0.009) at tumor presentation, after taking into account known prognostic factors such as age and gender of the patient and size and type of the tumor.
|
12727994 |
2003 |
|
Neoplasm Metastasis
|
0.380 |
AlteredExpression
|
phenotype |
BEFREE |
To investigate whether growth, invasion and metastasis of endometrial cancer cells is associated with neovascularization, the expressions of fibroblast growth factor-1 (acidic FGF), -2 (basic FGF) and -4 (hst-1) mRNAs and FGF-2 in endometrial cancers and normal endometria as controls were determined by reverse transcription-polymerase chain reaction-Southern blot and ELISA, respectively, and the relationships between their expressions and histological grades, grades of myometrial invasion or clinical stages of endometrial cancers were analyzed.
|
8685603 |
1996 |
|
Neoplasm Metastasis
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
FGF-2 appears as a promising candidate for monitoring the efficacy of emboli- zation in patients with osteolytic metastases.
|
29534588 |
2019 |
|
Neoplasm Metastasis
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
Thus, intervention and targeting of the FGF-2- and VEGF-C-induced angiogenic and lymphangiogenic synergism could be potentially important approaches for cancer therapy and prevention of metastasis.
|
22967508 |
2012 |
|
Neoplasm Metastasis
|
0.380 |
Biomarker
|
phenotype |
BEFREE |
The significance of this work is twofold: we have both uncovered genomic features by which E2F1 regulates metastasis and we have identified new pro-metastatic functions for the E2F1 target gene Fgf13.
|
31341204 |
2019 |
|
Malignant neoplasm of pancreas
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
In three cell lines (QG56 from lung cancer, T3M4 and Panc1 from pancreatic cancer), which produced both VEGF and FGF-2 at detectable levels, combined sVEGFR and sFGFR1 produced an enhanced inhibitory effect compared to their individual effects.
|
12136423 |
2002 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
BEFREE |
Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2.
|
27080571 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At pathophysiologically relevant concentrations found in tumor interstitial fluid, sHA is pro-proliferative, acts synergistically with VEGF-C and FGF-2, and stimulates the outgrowth of lymphatic capillaries in ex vivo lymphangiogenesis assays.
|
29282520 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRβ signaling pathways in tumor vascular remodeling.
|
29423271 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, in vivo, the FGFR inhibitor decreased C4-HI tumor growth, whereas FGF-2 was able to stimulate C4-HD tumor growth as MPA.
|
18767044 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our current study indicates that the PDGFRalpha-p70S6K pathway is an essential regulator for FGF-2-mediated therapeutic neovascularization, as well as for the host-derived vasculature but not tumors during tumor angiogenesis, via controlling continuity of expression of multiple angiogenic growth factors.
|
15059936 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth.
|
24874473 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Such downregulation of miR-15 and miR-16 in cancer-associated fibroblasts (CAFs) promoted tumor growth and progression through the reduced post-transcriptional repression of Fgf-2 and its receptor Fgfr1, which act on both stromal and tumor cells to enhance cancer cell survival, proliferation and migration.
|
21532615 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, loss of Fgf13 reduced in vitro cell migration, suggesting that Fgf13 may be critical for tumor cells to escape the primary tumor and to colonize the distal sites.
|
31341204 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In lung cancer cells, depletion of eIF4H enhances sensitization to chemotherapy, decreases cell migration and inhibits tumor growth in vivo, in association with reduced translation of mRNA encoding cell-proliferation (c-Myc, cyclin D1) angiogenic (FGF-2) and anti-apoptotic factors (CIAP-1, BCL-xL).
|
26498689 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, peritumoral mast cells provide FGF-2 to the tumor micro environment, which may contribute to their stimulating effect on angiogenesis.
|
20616342 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cytoplasmic PTTG expression correlated with expression of progesterone receptor (P = 0.009) and FGF-2 (P = 0.007) but not with other parameters such as the expression of estrogen receptor, tumor grade, and surgical stage.
|
18217976 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Increased FGF-2 mRNA expression was independently associated with the findings of lymph node invasion (R(2) = 0.71; P < 0.001) and distant metastasis (R(2) = 0.55; P = 0.009) at tumor presentation, after taking into account known prognostic factors such as age and gender of the patient and size and type of the tumor.
|
12727994 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
4E facilitates the synthesis of two powerful tumor angiogenic factors (VEGF and FGF-2) by selectively enhancing their translation.
|
10443829 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FGF-2 was downregulated in tumor tissue.
|
19245594 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A truncated form of 24kDa FGF-2 consisting of 86 NH(2)-terminal amino acids (ATE+31) inhibits cell migration in vitro and tumor development and angiogenesis in vivo.
|
19303400 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This indicates that HMW FGF-2 inhibits tumor growth in glioma cells by acting on cell-cycle progression and protein translation.
|
18930044 |
2008 |